Previous studies have shown that IL-6/STAT3 activation could attenuate sensitivity to EGFR-mutant NSCLC cells to EGFR-TKIs including icotinib [30] and gefitinib [31]. Here, IL6 is linked to non-small cell lung carcinoma.